ArticleLa Radiologia medica2023
The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Article in La Radiologia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Combined hepatocellular cholangiocarcinoma: A rare hepatic malignancy exhibiting concurrent imaging features of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Radiology case reports · 2026Article
- MRI features and LI-RADS categorization of combined hepatocellular-cholangiocarcinoma: a scoping review with prognostic implications.La Radiologia medica · 2026Article
- Combining preoperative clinical and ultrasound radiomic features to predict the predominant component of combined hepatocellular carcinoma-cholangiocarcinoma.BMC gastroenterology · 2026Article
- Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma‑cholangiocarcinoma.European radiology · 2026Article
- Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery.Journal of clinical medicine · 2025Review
- Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound.Diagnostics (Basel, Switzerland) · 2025Review
- All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.Journal of clinical medicine · 2025Review
- Can Peritumoral Radiomics Based on MRI Predict the Microvascular Invasion Status of Combined Hepatocellular Carcinoma and Cholangiocarcinoma Before Surgery?Journal of hepatocellular carcinoma · 2025Article
- MRI management of focal liver lesions: what a beginner cannot fail to know.Frontiers in oncology · 2025Review
- Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- Current advances and future directions in combined hepatocellular and cholangiocarcinoma.Gastroenterology report · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo investigate the significance of the predominant component of combined hepatocellular-cholangiocarcinoma (cHCC-CC) in terms of MRI manifestation and its potential prognostic value compared to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). MATERIALS AND
methodsA total of 300 patients with chronic liver disease from two centers were retrospectively enrolled, including 100 surgically proven cases of cHCC-CC, HCC, and ICC each. Univariate and multivariate regression analyses were performed to identify independent predictors for distinguishing HCC-predominant cHCC-CC and ICC-predominant cHCC-CC from HCC and ICC, respectively. Diagnostic models were constructed based on the independent features. Recurrence-free survival (RFS) was estimated and compared between groups.
resultsThe predominant component was an independent predictor for RFS in cHCC-CC (hazard ratio = 1.957, P = 0.044). The presence of targetoid appearance (odds ratio(OR) = 10.907, P = 0.001), lack of enhancing capsule (OR = 0.072, P = 0.001) and arterial peritumoral enhancement (OR = 0.091, P = 0.003) were independent predictors suggestive of HCC-predominant cHCC-CC over HCC; their combination yielded an area under the curve of 0.756. No significant differences were observed in RFS between HCC-predominant cHCC-CC and HCC (P = 0.864). Male gender (OR = 4.049, P = 0.015), higher alpha fetoprotein (OR = 16.789, P < 0.001) and normal carbohydrate antigen 19-9 (OR = 0.343, P = 0.036) levels, presence of enhancing capsule (OR = 7.819, P < 0.001) and hemorrhage (OR = 23.526, P = 0.004), and lack of targetoid appearance (OR = 0.129, P = 0.005) and liver surface retraction (OR = 0.190, P = 0.021) were independent predictors suggestive of ICC-predominant cHCC-CC over ICC; their combination yielded an area under the curve value of 0.898. ICC-predominant cHCC-CC exhibited poorer survival with shorter RFS than ICC (P = 0.009).
conclusionThe predominant histopathological component is closely related to the imaging manifestation of cHCC-CC; and more importantly, it plays a significant prognostic role, which may alter the RFS prognosis of cHCC-CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.